$ULBI

Ultralife Corp. Posts Quarterly Loss of $7.4M, Annual Revenue at $191.2M - News and Statistics

Ultralife Corp. reported a Q4 fiscal loss of $7.4 million, or 45 cents per share, though adjusted earnings were 12 cents per share. Quarterly revenue reached $48.5 million. For the entire fiscal year, the company posted an annual loss of $5.9 million, or 35 cents per share, with total annual revenue at $191.2 million.

Original reporting
Published Mar 10, 2026, 12:12 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 10, 2026, 12:58 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Ultralife Corp. Posts Quarterly Loss of $7.4M, Annual Revenue at $191.2M - News and Statistics — source image
Decision brief

The 30-second read

$ULBIBearishMed
01

Why it matters

The reported losses reflect challenges in the company's recent quarter, possibly affecting investor confidence.

02

Market read

The earnings report has high relevance for ULBI shareholders and potential investors, with immediate trading implications.

03

What to watch

Potential for a rebound if market sentiment improves or company announces strategic initiatives.

Timing: Immediate, as earnings reports influence trading decisions within days.

Background

Ultralife Corp. operates in the manufacturing sector, providing power solutions and communications equipment.

Company-level read

Ticker impact

$ULBIBearishHigh confidence
Context

High relevance due to direct financial performance impact.

Expected impact

Potential short-term decline of 5-10% due to earnings miss and bearish sentiment.

Evidence & confidence

The substantial losses and negative analyst sentiment suggest a likely downward price movement in the near term, especially given the high relevance score.

Market effects

Potential negative sentiment affecting the manufacturing and industrial sectors.

Limited, as company performance is specific and not indicative of broader regional trends.

Minimal, given the company's size and market influence.

Counterpoint

The company's adjusted earnings suggest underlying operational strength; the losses may be temporary or due to one-time charges.

Key entities

  • Ultralife Corp.

    A manufacturer of power and communications solutions.

Related articles

$ULBIMedAI 8/10

Ultralife (ULBI) Q2 2026 Earnings Call Transcript

Ultralife (ULBI) reported Q2 FY2026 revenue of $47.9 million, down 1.3% year over year, with GAAP EPS of $0.15. Gross margin rose to 28.9% on a 500 bps increase, aided by a $1.1 million IEEPA tariff refund. Backlog hit a record $117.5 million, up 39% from a year earlier, and July backlog neared $130 million.

$ULBIMed

ULTRALIFE CORP (ULBI): Results of Operations and Financial Condition

ULTRALIFE CORP (ULBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ultralife Corporation Reports Second Quarter Results NEWARK, N.Y. – August 7, 2026 -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the second quarter ended June 30, 2026 with the following results: ● Sales of $47.9 million compared to $48.6 mil

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.